Clinical trial
Mepolizumab As a Steroid Sparing Treatment Option in the Churg Strauss Syndrome
NCT00527566 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Mepolizumab As a Steroid Sparing Treatment Option in the Churg Strauss Syndrome
- Lead sponsor
- Brigham and Women's Hospital
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- September 30, 2007
- Completion date
- August 31, 2009
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
churg strauss syndrome